ABSTRACT Lung cancer is the most lethal cancer type worldwide, with the majority of patients presenting with advanced stage disease. Targeting early stage disease pathogenesis would allow dramatic improvements in lung cancer patient survival. Recently, cell migration has been shown to be an integral process in early lung cancer ontogeny, with preinvasive lung cancer cells shown to migrate across normal epithelium prior to developing into invasive disease. TP53 mutations are the most abundant mutations in human nonsmall cell lung cancers and have been shown to increase cell migration via regulation of RhoGTPase protein activity. In this review, we explore the possibility of targeting TP53-mediated Rho-GTPase activity in early lung cancer and the opportunities for translating this preclinical research into effective therapies for early stage lung cancer patients.
Introduction
Lung cancer is the most lethal cancer type worldwide, with a mortality rate greater than breast, colorectal and prostate cancer combined [1] . Nonsmall cell lung cancers (NSCLCs) account for ∼85% of disease [2] and include squamous cell carcinoma (SqCC), adenocarcinoma (ADC) and large cell carcinoma. Although 5-year post-operative survival is 50% for early-stage (stage I/II) NSCLC, >50% of patients present with stage IV disease that is associated with an abysmal 2% 5-year survival [3] . This is due to our limited understanding of the pathomechanisms driving lung cancer ontogeny, as well as a lack of effective biomarkers and screening tools for diagnosing patients with early stage disease. Thus, in order to identify and treat lung cancers more effectively, an improved understanding of the biochemical, molecular and cellular changes that accompany early lung cancer development is required.
It has been noted through post mortem studies and in patients undergoing longitudinal bronchoscopic surveillance that both preinvasive lesions and invasive SqCCs frequently develop at widely dispersed anatomical locations [4] [5] [6] . Indeed, in surveillance studies using autofluorescence bronchoscopy (AFB) and computed tomography, almost 60% of invasive lung cancers were observed in anatomically distinct sites from initially detected preinvasive lesions [7] . More recently, we found that preinvasive SqCC lesions exhibiting TP53 mutations invariably spread throughout the bronchial tree via discontinuous cell migration prior to disease progression [8] . These observations suggest that epithelial cell migration is an integral component of NSCLC development. In this review we focus on the role of cell migration as a potential therapeutic target for early lung cancers.
TP53 mutation, Rho-GTPase signalling and cancer cell migration TP53 is the most consistently and frequently mutated gene in all NSCLCs, with mutations observed in >80% of SqCCs [9] and >45% of ADCs [10] . Functionally, wild-type TP53 proteins play critical roles in DNA repair, cell cycle regulation, apoptosis and inhibition of cell migration [11] . At a molecular and cellular level, mutations in TP53 promote increased cancer cell migration by altering the cell's internal cytoskeleton via indirect regulation of the Rho-GTPase family of proteins [12] .
Rho-GTPase proteins coordinate cellular movement by promoting a "grow, grip, pull" system involving cytoskeletal growth at the cell's leading edge, adhesion to the extracellular matrix (ECM) and cytoskeletal contraction to pull the cell forward [13] . Rho-GTPases cycle between an inactive GDP-bound state to the active GTP-bound state upon activation by guanine nucleotide exchange factors (GEFs) [14] . The activation of these GEFs are regulated by upstream phosphoinositide 3-kinase (PI3K) [13] . Thus, PI3K activity, via signalling from membrane-associated receptor tyrosine kinase proteins, regulates Rho-GTPase activation and cell migration (figure 1).
Well-studied Rho-GTPase family members involved in this cell migration system include RhoA, Rac1 and Cdc42, each of which has important roles in the regulation of cell motility. Generally, Cdc42 functions to regulate cell polarity and the formation of actin microspikes and filopodia formation, while Rac1 mediates the formation of larger membrane protrusions (lamellipodia) at the leading edge of cell. Finally, RhoA is involved in focal adhesion formation, actomyosin contraction, stress fibre formation and retraction of the cell's tail [15] (figure 2). Additional components of this system include effector proteins such as Rho-associated kinase (ROCK) that "grow" the actin-based cytoskeleton, integrins that "grip" the ECM and myosin proteins bound to this actin cytoskeleton that provide contractile "pull" forces. Downstream of Rho-GTPases, other effector proteins including mDia, WAVE, N-WASP and PAR6 also coordinate Rac1, RhoA and Cdc42 functions including actin polymerisation, actomyosin contraction and regulation of cell polarity (figure 3) [16, 17] .
In normal, noncancerous cells, activation of TP53 following DNA damage or other cellular stress increases phosphatase and tensin homologue (PTEN) activity, leading to inhibition of PI3K, inhibition of downstream GEF activation and reduced Rho-GTPase-dependent cell migration (figure 1). However, in cells exhibiting mutant TP53 this process is disrupted leading to a lack of PTEN-mediated PI3K inhibition, ectopic GEF signalling and enhanced cell migration. In particular, elegant studies using fluorescence lifetime imaging (FLIM)-fluorescence resonance energy transfer (FRET) microscopy in TP53-mutant pancreatic ductal adenocarcinoma cells demonstrate increased motility and invasion in three-dimensional assays in vitro and in vivo [18] . Similarly, fibroblasts derived from TP53-deletion mice showed marked upregulation of GTP-bound RhoA activity and an increased capacity to migrate and invade in comparison with their wild-type counterparts [19] . In addition, human melanocytes with mutated TP53 demonstrated an almost five-fold increase in GTP-bound RhoA activity, coupled with increased migratory capacity [19] . Furthermore, TP53 was found to regulate Cdc42-mediated filopodia formation and cell polarisation in mouse embryonic fibroblasts (MEFs), and TP53-deficient MEFs exhibited constitutive filopodia and an increased ability to migrate [20] . Thus, a clear regulatory interplay exists between TP53 mutations and increased Rho-GTPase activity, contributing to enhanced cancer cell migration. Interestingly, genes encoding Rho-GTPases themselves are only rarely mutated in human cancers [21, 22] , despite their markedly elevated expression and activity [23] . This observation lends further support to the indirect, upstream role of TP53 in regulating activity of these key migratory proteins. Downstream of Rho-GTPases, altered expression of numerous effector proteins including ROCK2, LIMK1 and myosin light-chain (MLC) kinase through altered transcriptional regulation or mutation have been implicated in a variety of metastatic cancers, including both ADC and SqCC NSCLCs [24] [25] [26] (figure 3). These findings suggest an important role of downstream Rho-GTPase pathway components in regulating tumour cell migration and subsequent disease progression.
Therapeutic targeting of cancer cell migration
The development of novel therapies to prevent NSCLC progression represents an unmet need in cancer therapy. Reducing preinvasive cancer cell migration speaks to this ideal and the development of pharmacotherapies to reduce tumour cell migration has the potential to improve overall disease mortality. Targeting Rho-GTPase-dependent signalling is attractive as a potential cancer therapy given that the effects of TP53 mutation on cancer cell migration are reversible following RhoA and ROCK inhibition [27] . Towards this end, the small molecule ROCK inhibitor Y27632 has been shown to inhibit migration and invasion in a variety of cancer cell types in vitro, including pancreatic adenocarcinoma [18] , melanoma [19] and invasive oesophageal carcinoma [28] . Similarly, ROCK inhibition with the small molecule H-1152 reduced in vitro migration of the murine melanoma cell line B16F10 and limited the cells' ability to form pulmonary metastases in vivo [29] . Clinically, the potent ROCK inhibitor and vasodilator fasudil is in commercial use in Japan, where it has been shown to be a safe and well-tolerated drug used to prevent cerebral vasospasm post-subarachnoid haemorrhage [30] . Similarly, the direct RhoA inhibitor BA-210, used to treat spinal cord injuries, also has a good safety profile in humans [31] . However, the effect of these drugs on cell migration is as yet unknown.
Upstream of Rho-GTPase signalling, PI3K inhibitors have been explored as potential cancer therapies [32] , and several of these are either in use or currently undergoing clinical trials in a variety of human cancers [33] . Notably, the PI3K inhibitor idelalisib is currently approved to treat relapsed chronic lymphocytic leukaemia (CLL), and has recently been approved by the European Medicines Agency for the first-line treatment of CLL patients with TP53 mutations who are not fit for first-line chemotherapy [34] . Targeting PI3K signalling is also of growing interest in the treatment of NSCLC [35] , although the effect of PI3K inhibition on lung cancer cell migration remains unknown. Rapamycin, an immunosuppressant and well-known inhibitor of PI3K/ mTOR activity, has also demonstrated promising anticancer effects in solid tumours [36, 37] . Interestingly, rapamycin has been shown to inhibit cancer cell migration in vitro via suppression of mTOR-mediated lamellipodia formation, actin reorganisation and focal adhesion formation [38] . These effects were Rho-GTPase dependent, with reduced RhoA, Rac1 and Cdc42 expression in rapamycin-treated cells [39] .
In addition to upstream activators and downstream effectors, localisation of Rho-GTPase proteins at the plasma membrane is critical for effective signalling, and is achieved by a series of post-translational modifications including C-terminal cysteine prenylation [40] . Rho-GTPase prenylation is dependent on geranylgeranyltransferase-I, and efficient enzyme activity is dependent on a steady supply of geranylgeranyl pyrophosphate (GGPP) within the cell, the synthesis of which is rate-limited by HMGCoA-reductase. Indeed, HMGCoA-reductase inhibitors (statins) have been shown to reduce Rac1 association with cell membranes and subsequently reduce Rac1 cellular effects, including cell morphology and phagocytosis [41] . Simvastatin has been shown to inhibit migration of human and murine microglial cells at baseline and in response to chemokine stimulation, with associated distorted actin distribution [42] . This effect is reversed by co-incubation with L-mevalonate, indicating an inhibitory dependence on disruption of the mevalonate pathway and HMG-CoA reductase activity [42] . Similarly, treatment of human cultured prostate cancer cells with simvastatin or rosuvastatin reduced colony-forming ability and migration towards the powerful chemoattractant bone marrow stroma, with normal migratory behaviour restored with the addition of mevalonate or GGPP [43] . In addition, epidemiological data demonstrate lower rates of prostate cancer progression in patients taking statins [44] [45] [46] .
Despite these positive findings, Rho-GTPase inhibition is not without challenges and the use of Rho-GTPase inhibitors for human lung cancers remains unexplored. Rho-GTPase is heavily involved in organ development and repair, making delivery of broad-acting inhibitors potentially precarious. In utero, murine germline ROCK1 deletion causes defective eyelid closure, omphalocoele (nonclosure of the ventral body wall) and widespread epithelial dysfunction [47] . Similarly, 90% of ROCK II knockouts die in utero due to placental dysfunction and intrauterine growth retardation [48] . In normal human lung epithelial cells, Rho-GTPase activity is essential for normal wound repair [49, 50] . However, in bovine epithelial cells, RhoA inhibition via PKC activation was associated with improved wound closure [51] . Thus, the precise interplay of Rho-GTPase activity regulating normal and cancerous lung epithelial cell migration remains unclear. It may therefore be a more sensible approach when designing potential cancer therapeutics to target downstream effector proteins such as ROCK and mDia, rather than Rho-GTPase proteins themselves.
Future directions
Given the disparity in mechanisms underlying cell migration across tissue types, it remains of critical importance to characterise the role of various Rho-GTPase pathway components in normal and cancerous lung epithelial cell migration. Towards this end, methods have recently been developed to isolate and expand primary human bronchial epithelial cells that maintain a normal karyotype and multipotent differentiation capacity [52] . In addition, murine models of both human adeno and squamous NSCLCs, generated via targeted transgenesis or cutaneous application of chemical carcinogens, are available [53] [54] [55] [56] . Taken together, these in vitro and in vivo models offer unique opportunities for monitoring the effects of Rho-GTPase activity on lung epithelial cell migration. In addition, human bronchoscopic surveillance using AFB will allow accurate assessment of the migration of clonally distinct preinvasive SqCC lesions. Although the numbers of patients undergoing routine surveillance bronchoscopy remain small, these studies should nonetheless improve our understanding of the earliest stages of disease pathogenesis. Interestingly, the widespread use of statins within these patients may also permit retrospective analysis of the effects of statin-dependent Rho-GTPase inhibition on preinvasive disease progression.
Clinically, targeting the Rho-GTPase signalling pathway to reduce early NSCLC disease progression appears to hold promise. Future in vitro and in vivo studies involving small molecule Rho-GTPase inhibitors will allow precise characterisation of the molecular pathways involved in preinvasive lung cancer cell migration, and propel the use of targets of cell migration towards clinical benefit. Furthermore, the wealth of therapies already available and licenced for human use provides great opportunity for rapid translation of preclinical data into effective therapies for lung cancer patients.
